Ozempic & Mounjaro in Morocco: 2026 prices, availability — full comparison

For three years now, two names have kept resurfacing in Moroccan endocrinology consultations: Ozempic and Mounjaro. The first has become a worldwide phenomenon, both a treatment for type 2 diabetes and a Hollywood-co-opted star for its weight-loss effect. The second, more recent, posts even more impressive figures in clinical trials. The Moroccan reality in 2026 is more nuanced: Ozempic is officially marketed for diabetes, but only since November 2025 (before that, under the pressure of global demand, it could only be obtained abroad); Mounjaro holds a marketing authorisation but no public price yet, so it is not marketed and is only accessible through personal importation. This article rigorously compares the two molecules, semaglutide and tirzepatide, in light of the SUSTAIN, STEP, SURPASS and SURMOUNT trials, and resets each product in Moroccan practice — real prices, regulatory status, available alternatives, counterfeiting risks linked to parallel circuits, and the right approach when a patient asks for one "to lose weight".

01Semaglutide vs tirzepatide: the pharmacological difference#

Both molecules belong to the incretin receptor agonist family, gut hormones released after meals that regulate blood glucose and satiety. But they do not target the same receptors, which explains most of their clinical differences.

Semaglutide, the active ingredient in Ozempic (Novo Nordisk laboratories), is a pure agonist of GLP-1 receptors (Glucagon-Like Peptide-1). Its peptide structure has been modified to resist enzymatic degradation by DPP-4, giving it a half-life of around 7 days and allowing weekly subcutaneous administration. Semaglutide stimulates glucose-dependent insulin secretion (therefore without major hypoglycaemia risk in monotherapy), inhibits glucagon secretion, slows gastric emptying and acts on hypothalamic satiety centres to reduce spontaneous calorie intake. This central action explains the weight loss observed in diabetic patients, which has become a sought-after effect well beyond the initial indication.

Tirzepatide, the active ingredient in Mounjaro (Eli Lilly laboratories), is a more recent molecule and conceptually different: it is a dual GIP/GLP-1 agonist. It simultaneously activates the GLP-1 receptors and those of GIP (Glucose-dependent Insulinotropic Polypeptide), the second gut incretin historically overlooked by the pharmaceutical industry but rehabilitated by recent preclinical work. Adding GIP activity appears to potentiate both glycaemic and weight-loss effects without proportionally amplifying digestive side effects. Tirzepatide also has a half-life of about 5 days, permitting weekly injection.

On paper, tirzepatide therefore promises superior efficacy compared with semaglutide, which the head-to-head clinical trials have indeed confirmed. But this statistical superiority does not mechanically translate into clinical benefit for every patient, and tirzepatide exposes to a comparable, even slightly higher, frequency of digestive effects (nausea, vomiting, diarrhoea). The choice between the two molecules therefore never reduces to "which one produces more weight loss" — it integrates individual tolerance, cardiovascular profile, cost, and real-world availability in Morocco.

02AMM indications: type 2 diabetes vs obesity#

This is where the main source of patient confusion in Morocco sits. Ozempic is authorised by the Moroccan AMMPS (Agence marocaine du médicament et des produits de santé, created by law 10-22 to take over the missions of the former Direction du Médicament et de la Pharmacie), as well as by the European EMA and the US FDA, only for the treatment of inadequately controlled type 2 diabetes, in combination with metformin or other antidiabetic agents. No marketing authorisation covers, in 2026, its use in a non-diabetic overweight or obese patient in Morocco.

To treat obesity specifically with semaglutide, Novo Nordisk markets a distinct product under the name Wegovy, dosed at 2.4 mg weekly (vs 0.25 to 2 mg for Ozempic), validated by the STEP-1 to STEP-5 trials published from 2021 onwards (STEP-1 in the New England Journal of Medicine, the others in The Lancet, JAMA and Nature Medicine). Wegovy is not marketed in Morocco in 2026, because the specialty has not been locally registered. This absence leaves a regulatory vacuum that popular demand has filled by the off-label use of Ozempic — i.e. its diversion by non-diabetic patients seeking weight loss.

On the tirzepatide side, the same pattern repeats. Mounjaro initially carries the "type 2 diabetes" indication in the countries where it is marketed. Eli Lilly obtained US authorisation in 2023 for the obesity indication under the name Zepbound, on the basis of the SURMOUNT-1 to SURMOUNT-4 trials. In Morocco, Mounjaro holds an AMM (KwikPen 2.5 to 15 mg) but no public price has been set, so it is not marketed; Zepbound is not registered.

Saxenda (liraglutide 3 mg/day, daily GLP-1 agonist), however, holds a Moroccan AMM for obesity since 2024, although the AMMPS database lists it as not marketed, which makes it, paradoxically, the only GLP-1 legally prescribable in first-line for weight loss in Morocco. We will return to this.

03Ozempic in Morocco: status, price, where to buy#

Ozempic has been marketed in Morocco since November 2025 in three strengths: 0.25 mg, 0.5 mg and 1 mg as a weekly injection, packaged as a pre-filled injector pen. The 2 mg strength exists internationally but is not registered in Morocco. The legal circuit is strict: delivery in a community pharmacy on prescription from a doctor (general practitioner, endocrinologist or diabetologist), with an initiation schedule imposed by the SmPC — 0.25 mg for 4 weeks, then 0.5 mg for at least 4 weeks, then adjustment to 1 mg if needed for glycaemic control.

The official public price, set by ministerial order, is 1,099 MAD per pen whatever the strength (0.25 mg initiation strength, 0.5 mg or 1 mg; 4 doses per pen), each pen covering about 4 weeks of treatment. By comparison, the same pen costs around 77 € in France (price before national health insurance reimbursement) and 349 dollars a month in the United States at Novo Nordisk's self-pay price without insurance. Morocco therefore sits above the French price but below the US self-pay price, which paradoxically contributes to the appeal of the Moroccan circuit for some MRE on reverse medical travel.

The on-the-ground reality was long much harder. Until its official launch in November 2025, Ozempic was not marketed in Morocco and could only be obtained abroad. The cause is global: explosive demand in the United States and Europe, fuelled by Wegovy prescriptions and media buzz, has forced Novo Nordisk to ration secondary markets. Moroccan diabetic patients regularly find themselves having to switch therapeutic class temporarily, fall back on an alternative available GLP-1 (Trulicity, Victoza), or delay the step-up from 0.5 mg to 1 mg by several weeks. This supply instability is, for the Moroccan endocrinologist, a concrete argument against prescribing Ozempic in first-line for a newly diagnosed patient — other molecules in the same class have better availability. For diabetes follow-up, see also the related article on oral antidiabetics Apixia, Glucophage, Janumet.

04Mounjaro in Morocco: importation and alternatives#

As of October 2026, Mounjaro is still not officially marketed in Morocco. It has nevertheless obtained an AMM (KwikPen 2.5 to 15 mg, Sothema), but the AMMPS lists no public price yet, and no launch date has been publicly announced. This absence leaves three routes, all problematic.

The first is legal personal importation, via the route of a named-patient temporary importation authorisation issued by the AMMPS (which took over the missions of the former DMP). The procedure, theoretically possible, requires a prescription from a Moroccan doctor, a documented compelling medical reason (typically a failure or contraindication of all marketed alternatives), and an administrative delay of at least several weeks. In practice it remains very rarely used because it is cumbersome and little known to prescribers.

The second route is purchase during a trip to Europe, Turkey or the United Arab Emirates, where Mounjaro is available. Prices observed in 2026 are around 250 to 400 € per month in Europe depending on the dose, and substantially less in Turkey (about 150–200 €). Travellers can bring back a quantity intended for personal use provided they have a valid prescription. This route is used by part of the Moroccan diaspora and MRE, but it raises the question of therapeutic continuity: what does the patient do if they can no longer access the product after a few months? Abrupt withdrawal of a GLP-1 in a poorly controlled diabetic patient exposes to a glycaemic rebound. For MRE who wish to be followed in Morocco, the Sahha medical tourism network identifies realistic options in private endocrinology.

The third route is the informal circuit: online purchases from non-approved foreign websites, resale on social media, undeclared parallel importation. This route is formally illegal under Moroccan law 17-04 on the Code of Medicine and Pharmacy, which reserves the importation of medicines to laboratories holding an AMM or to approved importers. Above all, and this is the crucial point, it exposes to counterfeiting risk.

05Comparative efficacy: HbA1c and weight loss#

On glycaemic control, both molecules are clearly superior to classical oral antidiabetics. The SUSTAIN programme (semaglutide unabated sustainability) published from 2016 to 2018 seven randomised controlled trials involving more than 8,000 patients. SUSTAIN-1 (semaglutide vs placebo in monotherapy) showed a mean HbA1c drop of 1.5% with the 1 mg dose; SUSTAIN-7 (semaglutide vs dulaglutide) demonstrated the superiority of semaglutide over dulaglutide (Trulicity) with an HbA1c differential of about 0.4% in favour of semaglutide. SUSTAIN-6, a cardiovascular safety trial conducted in 3,297 high-risk patients, showed a 26% reduction in the major adverse cardiovascular event composite (MACE) under semaglutide vs placebo, validating use of the molecule in coronary diabetic patients.

The SURPASS programme (pivotal study of tirzepatide for diabetes) compared tirzepatide with various comparators: insulin degludec, insulin glargine, semaglutide 1 mg. SURPASS-2, published in 2021 in NEJM, is the only head-to-head trial of semaglutide vs tirzepatide in type 2 diabetes. In 1,879 type 2 diabetic patients, tirzepatide 15 mg/week induced an HbA1c drop of 2.30% vs 1.86% for semaglutide 1 mg, i.e. a differential of 0.45% in favour of tirzepatide. Mean weight loss at 40 weeks was 11.2 kg for tirzepatide 15 mg vs 5.7 kg for semaglutide 1 mg — about 5.5 kg additional.

On non-diabetic obesity, the STEP programme (semaglutide 2.4 mg, Wegovy) showed mean weight loss of 14.9% of baseline weight over 68 weeks in STEP-1. The SURMOUNT programme (tirzepatide for obesity) published in 2022 in NEJM the results of SURMOUNT-1: in 2,539 non-diabetic obese patients, tirzepatide 15 mg induced mean weight loss of 22.5% over 72 weeks, vs 2.4% on placebo. SURMOUNT-2, conducted in 938 obese diabetic patients, showed a 15.7% loss at 72 weeks on tirzepatide 15 mg.

The SURMOUNT-5 trial (NEJM, 2025) directly compared the two molecules in 751 non-diabetic obese patients: at 72 weeks, weight loss reached 20.2% on tirzepatide (10 or 15 mg) vs 13.7% on semaglutide (1.7 or 2.4 mg). This 6.5-point gap confirms the indirect comparison of STEP-1 and SURMOUNT-1 data, which suggested a tirzepatide advantage of around 6 to 8 percentage points of weight loss. This difference is clinically meaningful, but it does not make tirzepatide a "miracle molecule": one in five patients in SURMOUNT-1 lost less than 10% of baseline weight, and weight regain after treatment discontinuation remains the rule: one year after stopping, participants in the STEP-1 extension had regained two-thirds of the weight lost, and the STEP-4 withdrawal trial showed weight regain in patients switched to placebo.

06Adverse effects: nausea, pancreatitis, gastroparesis#

Both molecules share a profile of digestive adverse effects that dominate the patient experience. Nausea affects about 12 to 20% of patients at diabetes doses (US labels of Ozempic and Mounjaro), and up to 44% at the obesity dose of semaglutide (Wegovy), on initiation and at each dose increase, generally mild to moderate, transient over 1 to 4 weeks, and improved by classical dietary advice: smaller and split meals, low in fat, avoiding lying down immediately after meals. Vomiting is less frequent (5 to 9% at diabetes doses) but may impose a transient interruption or dose reduction. Diarrhoea and constipation follow comparable frequencies. These effects are systematically more marked at the initiation step and during dose escalations, which justifies the progressive titration imposed by the SmPC.

Four more serious adverse effects deserve specific attention. Acute pancreatitis has been the subject of an ANSM safety bulletin since 2013 and of several EMA alerts. The absolute risk remains low (incidence comparable to placebo in recent meta-analyses including the SUSTAIN and SURPASS trials), but it calls for great caution in patients with a personal history of pancreatitis (the European and US labels do not make it a formal contraindication) and immediate treatment discontinuation in the face of any persistent epigastric abdominal pain radiating to the back.

Severe gastroparesis has been the most publicised effect since 2023, following several case reports; in September 2023, the FDA also added ileus (intestinal obstruction) to the post-marketing adverse reactions in the Ozempic label. Slowed gastric emptying is the sought pharmacological effect of GLP-1s; in some patients, it tips into clinically meaningful gastroparesis with food vomiting, epigastric pain, major loss of appetite and excessive weight loss. Treatment discontinuation allows reversibility in the great majority of cases, but a few published series report persistence over several months. Moroccan patients warned of this risk should be able to quickly contact their endocrinologist or use a Sahha Live teleconsultation if suggestive symptoms appear.

The risk of worsened diabetic retinopathy when HbA1c drops rapidly was documented in SUSTAIN-6: overly brutal glycaemic intensification in a patient with pre-existing retinopathy may induce transient progression. The rule remains an ophthalmological assessment before initiation in any long-standing diabetic patient.

Finally, the theoretical thyroid risk (medullary thyroid carcinoma observed in rodents in preclinical studies) led the US FDA to formally contraindicate both molecules in patients with a personal or family history of medullary carcinoma or MEN 2 (the European Ozempic label does not include this contraindication). No signal has been detected in humans in clinical trials.

07Off-label weight loss: the Moroccan grey zone#

The diversion of Ozempic for weight-loss purposes in non-diabetic patients has become, since 2023, the most delicate topic in Moroccan endocrinology. On the regulatory front, law 17-04 on medicines and the DMP circular on pharmaceutical promotion forbid any promotion of a medicine outside its AMM. Promoting Ozempic for weight loss is therefore formally illegal. At its launch in November 2025, it was recalled that doctors are not authorised to prescribe it for weight loss: a doctor who did so would step outside the AMM and engage their personal responsibility.

This grey zone fuels several concrete drifts. The first is circuit diversion: diabetic patients are refused their Ozempic in the pharmacy because a limited stock is partially used up through accommodation prescriptions for non-diabetic patients. The second is prescription at insufficient dose: a non-diabetic patient often tolerates the 1 mg step poorly and stops at 0.5 mg, a dose at which weight loss is modest and regain rapid upon discontinuation. The third is the emergence of a parallel market where Ozempic is resold outside the pharmacy circuit, with a major counterfeiting risk that we will detail below.

The Moroccan endocrinologist in 2026 must therefore hold a clear line: managing obesity goes through a comprehensive assessment (anthropometry, comorbidities, eating behaviour, physical activity, psychological context), a structured therapeutic project, and — if a pharmacological option is chosen — preferential use of products actually authorised for that indication in Morocco, namely Saxenda (liraglutide) or, pending Wegovy/Mounjaro, referral to a structured medical tourism programme for patients who qualify.

08Available alternatives: Trulicity, Saxenda, Victoza#

In 2026, Morocco offers several other GLP-1s that are often better available than Ozempic. Trulicity (dulaglutide) from Eli Lilly is a weekly GLP-1 agonist marketed in Morocco in 0.75 mg and 1.5 mg strengths (the 3 mg and 4.5 mg strengths are not registered there). The official public price in 2026 is 900 MAD per box of 4 pens for both 0.75 mg and 1.5 mg (the 1.5 mg fell from 1,171 to 900 MAD in January 2026). Trulicity is not authorised for obesity and is strictly reserved for type 2 diabetes. Its efficacy on HbA1c is slightly inferior to that of semaglutide (0.4% differential in SUSTAIN-7), and its effect on weight is more modest (mean loss of 2 to 3 kg). But its regular availability in pharmacy and its cardiovascular profile validated by the REWIND trial make it a credible alternative in the stable diabetic patient.

Victoza (liraglutide 1.2 or 1.8 mg/day) is Novo Nordisk's historical daily GLP-1 agonist, marketed for type 2 diabetes for over ten years. Its main drawback is the daily injection, which degrades adherence compared with weekly products. Its public price is 1,193 MAD per box of 2 pens, i.e. about one month at 1.2 mg/day. Victoza is still prescribed in some patients already balanced under this treatment who do not wish to change.

Saxenda (liraglutide 3 mg/day), the same molecule at a higher dose, is authorised for obesity (BMI >= 30, or >= 27 with comorbidity) with a Moroccan AMM obtained in 2024, but the AMMPS database lists it as not marketed. It is, to date, the only GLP-1 legally prescribable in Morocco for weight loss. Its efficacy (mean loss of about 5 to 8% of baseline weight at one year) is more modest than that of Wegovy or Zepbound, but its regulatory framework is unambiguous. Its public price of 2,625 MAD per box of 5 pens (about one month at 3 mg/day) remains a significant barrier for the majority of Moroccan patients. To direct an overweight patient towards the right consultation, the directory endocrinologist in Casablanca lists the practitioners in the Sahha network.

Other modern antidiabetics — SGLT2 inhibitors such as empagliflozin (Jardiance) and dapagliflozin (Forxiga) — also exert a modest weight-loss effect (2 to 3 kg) with demonstrated cardiorenal protection. They can be combined with a GLP-1 in the multi-complicated diabetic.

09Cost and AMO/ALD reimbursement#

Coverage of GLP-1s by ANAM (Agence Nationale de l'Assurance Maladie) in Morocco is strictly limited to type 2 diabetes documented in ALD (long-term disease). The patient must hold a complete file validated by the medical adviser of CNOPS or CNSS, and the medicine must be prescribed by an endocrinologist or hospital diabetologist within an indication conforming to the SmPC. The reimbursement rate varies by regime: 70 to 100% for recognised ALD, with an annual ceiling and a defined care basket.

At its launch in November 2025, Ozempic was covered neither by CNOPS nor by CNSS (AMO), according to Moroccan press reports; only some private insurers could cover it. Saxenda is not reimbursed because its indication (obesity) is not recognised as ALD in the 2026 Moroccan basket, which weighs heavily on adherence. Trulicity and Victoza follow the same regime as Ozempic. Mounjaro, not marketed, obviously enjoys no coverage at all.

For a non-diabetic patient seeking weight loss, no GLP-1 is covered by Moroccan insurances in 2026. The monthly cost remains entirely on the patient, which de facto constitutes a strong socio-economic filter. This inequality of access is one of the arguments raised by learned societies — Société Marocaine d'Endocrinologie, Diabétologie et Nutrition (SMEDIAN) in particular — to advocate with the authorities for a gradual extension of reimbursement, conditioned on rational use.

10Shortages and counterfeits: how to protect yourself#

Until November 2025, Ozempic was not marketed in Morocco and could only be obtained abroad. The situation changed in late 2025 with its official launch in pharmacies, but the supply hazard remains. Practically, the Moroccan patient on Ozempic must anticipate: do not wait for the last week to renew, signal any delay to the doctor, and identify a backup molecule ready to substitute in case of a prolonged shortage (Trulicity, Victoza, or even a transient switch to insulin therapy).

The counterfeiting risk is the flip side of the shortage. In June 2024, the WHO published an alert (No. 2/2024) and a warning about falsified Ozempic pens detected in 2023 in Brazil, the United Kingdom and the United States, advising against purchases from unverified sources such as websites. The most dangerous counterfeits contained insulin instead of semaglutide, which can cause severe and potentially fatal hypoglycaemia. Others contained no active ingredient at all, or erratic doses.

A few simple rules to protect yourself: only buy in a Moroccan approved pharmacy, systematically refuse any online or social-media offer, check the integrity of the box (batch number, sealing, readable Datamatrix code), and report any unusual appearance of the pen (colour, consistency of the liquid visible in the window, behaviour of the dose selector). When in doubt, the pharmacist can query the laboratory via the Datamatrix code. The AMMPS, which took over the missions of the DMP, provides on its website for the reporting of substandard or falsified medicines.

11Sahha endocrinologist teleconsultation#

Supply instability, the need for progressive dose titration, monitoring of adverse effects, and therapeutic education make follow-up by an endocrinologist or diabetologist a critical point. For patients who cannot travel monthly, or who live outside major cities, Sahha Live teleconsultation allows continuous care by a qualified Moroccan endocrinologist, with electronic prescriptions, blood-glucose diary follow-up and referral to in-person consultation when needed. For MRE wishing to initiate or continue their treatment during a stay in Morocco, the Sahha medical tourism programme integrates an endocrinologist pathway with full work-up, prescription and remote follow-up.

Therapeutic education deserves specific attention: self-injection via the pen, rotation of injection sites (abdomen, thigh, arm), refrigerated storage of the unopened pen then room temperature after opening (up to 6 weeks per the references), and what to do if a dose is missed are points worth explaining to every patient. A fifteen-minute video consultation can clarify these aspects before the first injection and significantly improve adherence.

Article written with AI assistance and reviewed by the Sahha editorial team.

Medical disclaimer: This content is informational and does not in any way replace an individual medical consultation. The prescription of any GLP-1 treatment must be individualised and supervised by a physician.